TET2 and myeloid leukemia: To test whether TET inhibition by Epag imposes growth restrictions, particularly on TET2 knockout myeloid leukemia cells compared with WT cells, we tested isogenic THP1TET2KO cells generated using CRISPR-Cas9 and treated with increasing doses of Epag (Figure 5B).